Back to announcement
20260611_OMED_Laporan Informasi dan Fakta Material_32100356_lamp3.pdf
Other Text extracted OMEDSource file signed link, expires in 15 minutes
Extracted text 3
Page 1
PT Jayamas Medica Industri Tbk (OMED) Successfully Holds AGM,
EGM, and Public Expose 2026: Records Strong Growth, Declares
Dividend, and Outlines Expansion Strategy
Surabaya, June 10, 2026
PT Jayamas Medica Industri Tbk (IDX: OMED), a leading manufacturer and distributor of
medical devices and supplies in Indonesia, successfully held its Annual General Meeting of
Shareholders (AGM) and Extraordinary General Meeting of Shareholders (EGM) on Monday,
8 June 2026, at the Company’s production facility in Mojoagung, Jombang. On the same day,
the Company also conducted Public Expose, presenting its financial performance, growth
strategies, and management’s perspective on current market dynamics.
AGM Results: Approval of Financial Statements and Dividend Declaration
All five agenda items of the AGM were approved by shareholders with strong support.
Shareholder attendance reached 88.83% of total shares with voting rights. Key resolutions
adopted include:
• Approval and ratification of the Company’s Annual Report and Consolidated Financial
Statements for the fiscal year ended 31 December 2025, along with the granting of full
discharge and release of liability (acquit et de charge) to the Board of Commissioners
and Board of Directors.
• Determination of the use of Net Profit for fiscal year 2025, including the distribution of
a final cash dividend of Rp4.08 per share, equivalent to Rp110.4 billion, to
shareholders — reflecting the Company’s commitment to delivering consistent returns
to investors.
• Authorization granted to the Board of Commissioners to determine the remuneration
of the Board of Commissioners and Board of Directors.
• Delegation of authority to the Board of Commissioners to appoint an Independent
Public Accountant to audit the Company’s books for the fiscal year ending 31
December 2026.
• The Report on the Realization of Use of Proceeds from the Initial Public Offering was
presented as a report and did not require a vote.
EGM Results: Employee Share Ownership Program and Articles of
Association Amendment
The EGM also approved two strategic agenda items, with shareholder attendance reaching
88.78% of total shares with voting rights:
Page 2
• Approval of the transfer of Treasury Shares for the implementation of a Management
and/or Employee Stock Ownership Program (MESOP) for the Company’s employees,
Directors, and Commissioners, with an initial tranche of up to 17 million shares. The
exercise price is set at fair value on the grant date and shall not be lower than the
buyback price. A lock-up period of 12 calendar months applies.
• Approval of an amendment to Article 3 of the Company’s Articles of Association to align
its business activities with the Indonesian Standard Industrial Classification (KBLI)
2025, covering 11 primary and 4 supporting business activities relevant to the
Company’s medical device business.
Public Expose: Solid Financial Performance in 1Q26
During the Public Expose, management presented 1Q26 financial results reflecting significant
growth acceleration:
• Revenue grew 31.2% year-on-year (YoY) to Rp572.2 billion, driven by a significant
volume expansion of 54.1%.
• Gross profit margin improved to 36.0% from 33.7% in 1Q25, reflecting a better product
mix and operational efficiencies.
• EBITDA grew to Rp131.4 billion with EBITDA margin expanding to 23.0%.
• Net profit grew 35.4% YoY to Rp99.0 billion, with net profit margin remaining stable at
17.3%.
• The balance sheet remains highly healthy: current ratio of 11.1x with an interest-
bearing debt-to-equity ratio of only 0.01x, reflecting a strong capital structure virtually
free of financial debt obligations.
• Working capital management continued to improve: Accounts Receivable Days
declined to 46 days (from 53 days in 1Q25) and Inventory Days improved to 186 days
(from 195 days).
Organic Growth Catalysts for 2026
Management outlined four key strategic initiatives that will serve as the primary growth drivers
for the Company throughout 2026:
1. New Product: Intraocular Lens (IOL) for the Cataract Market
OMED will commence mass production of Intraocular Lenses (IOL) in Q4 2026. IOL is the only
definitive treatment for cataracts through a lens replacement procedure. Indonesia represents
a substantial addressable market: approximately 80% of blindness cases in Indonesia are
caused by untreated cataracts, with around 1.6 million people affected and 50% of cases still
untreated. The cataract surgery rate in Indonesia currently stands at approximately 2,300 per
million population per year — 2 to 3 times lower than neighboring countries. OMED’s entry
into this segment is expected to improve both the accessibility and affordability of IOL products
in the domestic market.
Page 3
2. New Retail Store Openings (Omnichannel)
The Company continues to expand its omnichannel retail network across multiple cities,
including the opening of a new OneMed Medicom location in Purwokerto. This expansion aims
to strengthen market penetration in the consumer retail segment and extend the Company’s
direct-to-customer service reach.
3. National Distribution Center (NDC) Jakarta
The Company is finalizing the construction of a new NDC in Pulo Gadung, Jakarta, which is
expected to be operational in 2026 with a warehouse capacity of approximately 5,000 m². This
facility will complement the existing NDC in Gresik, which has been serving Eastern Indonesia
since 2007, enabling more efficient distribution coverage across Western Indonesia.
Business Resilience Amid Currency Volatility and Global Geopolitical
Uncertainty
In response to questions regarding the impact of USD exchange rate volatility and global
geopolitical uncertainty, OMED management highlighted several key factors underpinning the
Company’s business resilience:
• Stable and inelastic demand: OMED’s product portfolio is predominantly composed of
consumable medical supplies that represent routine necessities for healthcare
facilities. Demand for these products is non-discretionary and relatively insensitive to
macroeconomic conditions. Additionally, the Company’s customer base of more than
2,000 hospitals and clinics tends to exhibit high loyalty and stickiness.
• Strong cash position and healthy cash flow: The Company holds a robust cash balance
of Rp1.3 trillion and maintains a clean balance sheet, with an interest-bearing debt-to-
equity ratio of just 0.01x as of 1Q26. This provides ample financial flexibility to navigate
potential cost increases arising from rupiah depreciation.
• Well-managed inventory levels: At the operational level, the Company maintains a
measured raw material inventory position, minimizing exposure to cost escalation from
currency fluctuations. Additionally, certain products carry a domestic component
content (TKDN) of over 40%, further mitigating the impact of exchange rate
movements on the Company’s cost of production.
For more information, contact:
Corporate Secretary & Investor Relations PT Jayamas Medica Industri Tbk
Email : corporate.secretary@onemed.co.id
ir@onemed.co.id
Website : www.onemed.co.id
Names mentioned 1 people and organisations named in the text · linked when the evidence is strong
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.